CANF - Can-Fite BioPharma Ltd.

NYSE American - NYSE American Delayed Price. Currency in USD
Show:
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
2022-12-31
2021-12-31
2020-12-31
2019-12-31
Total Revenue
817
810
853
763
2,032
Operating Expenses
Research Development
8,410
7,763
9,850
11,951
10,976
Selling General and Administrative
3,448
3,143
3,845
2,951
3,063
Total Operating Expenses
11,858
10,906
13,695
14,902
14,039
Operating Income or Loss
-11,041
-10,096
-12,842
-14,139
-12,007
Interest Expense
-
-
-
363
427
Total Other Income/Expenses Net
-283
-283
221
39
-242
Income Before Tax
-11,272
-10,173
-12,615
-14,443
-12,625
Income Tax Expense
0
0
0
0
0
Income from Continuing Operations
-11,272
-10,173
-12,615
-14,443
-12,625
Net Income
-11,272
-10,173
-12,615
-14,443
-12,625
Net Income available to common shareholders
-13,862
-10,173
-12,615
-15,158
-12,625
Basic EPS
-
-3.00
-9.00
-12.00
-42.00
Diluted EPS
-
-3.00
-9.00
-12.00
-42.00
Basic Average Shares
-
2,719
1,844
1,195
286.366
Diluted Average Shares
-
2,719
1,844
1,195
286.366
EBITDA
-
-10,096
-12,842
-14,068
-12,184